510(k) device
BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini
Biofire Diagnostics, LLC · Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF, Class II) · First FDA decision Feb 3, 2023, newest Aug 14, 2025COVID-19, flu and respiratory infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
510(k) pathway
Device trials
1
Naming "BIOFIRE SPOTFIRE"
MAUDE reports
0
Brand "BIOFIRE SPOTFIRE", since 2015
PubMed studies
8
Mentioning "BIOFIRE SPOTFIRE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
K243544 · Decided Aug 14, 2025 · 272 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing AgentsNational determinationOn the books150.7Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "BIOFIRE SPOTFIRE", any status and sponsor, newest update first.
BioMérieuxNot on our public-company list
NCT07513519 · 800 participants · Start Dec 22, 2025 · Primary completion Apr 30, 2026
Device: SPOTFIRE R/ST Diagnostic Test · For: Acute Respiratory Infections (ARIs)
Sites: Gardendale, Alabama; Hoover, Alabama
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BIOFIRE SPOTFIRE", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QOF
56 reports: 48 malfunction, 8 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Biofire Spotfire Respiratory/Sore Throat Panel REF: 423485Open, Classified
Z-2081-2026 · Started Apr 1, 2026 · Posted by FDA May 6, 2026
Reason given: Respiratory/sore throat panel test may result in false negative results and control failures.
Cause as FDA categorized it: Under Investigation by firm · Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF)
Published research
The most relevant PubMed records for "BIOFIRE SPOTFIRE"[tiab]. The summary above synthesizes these.
- Clinical Evaluation of the BIOFIRE SPOTFIRE Respiratory Panel.
Chan WS, Ho CW, Chan TC, et al. · Viruses · 2024Research Support, Non-U.S. Gov't
- Analytical performance evaluation of the biofire SPOTFIRE respiratory and sore throat panel.
Locher K, Torchinsky M, Belanger C, et al. · Diagn Microbiol Infect Dis · 2026Evaluation Study
- Combining an antibiotic stewardship program with a 15-pathogen viral panel to reduce inappropriate antibiotic prescribing.
Arnold CG, Furtado T, Bang H, et al. · Microbiol Spectr · 2026Research Support, N.I.H., Extramural
- Head-to-head comparison of the performance of BIOFIRE® SPOTFIRE® Respiratory/Sore Throat Panel, Cepheid Xpert® Xpress SARS-CoV-2/Flu/RSV and Cobas® SARS-CoV-2 & Influenza A/B assay for detection of respiratory viruses.
Banerjee D, Sasidharan A, Gummersheimer S, et al. · J Clin Virol · 2026Comparative Study
- Evaluating the Clinical Impact of BioFire Spotfire R/ST on the Management of Pediatric Respiratory Presentations in the Emergency Department: A Pre-Post Cross-Sectional Study in Chile.
Benadof D, Acuña M, Leiva Y, et al. · Viruses · 2026
- Evaluation of Cepheid Xpert Xpress CoV-2/Flu/RSV plus and the Biofire Spotfire R/ST Panel Mini using CLIA-waived devices.
Hoff JS, Athanasiou Kaatz N, Sabharwal L, et al. · J Clin Virol · 2026Evaluation Study
- Analysis of Macrolide Resistance in Bordetella pertussis Isolated from Japanese Children in 2025 Using Test Kit and Sequence Method.
Oishi T, Nakano T · Biomedicines · 2026
- Point-Of-Care Respiratory Diagnosis and Antibiotic Utilization in the Emergency Department: A Prospective Evaluation of Multiplex PCR.
Meltzer AC, Payette C, Heidish R, et al. · Acad Emerg Med · 2026Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code QOF.
- Xpert Xpress CoV-2/Flu plusCepheid® · 510(k) 2026
- QIAstat-Dx Respiratory Panel PlusQIAGEN GmbH · 510(k) 2025
- Panther Fusion SARS-CoV-2/Flu A/B/RSV assayHologic, Inc. · 510(k) 2024
- BIOFIRE Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics · De Novo 2026
- FINDER Flu A&B/SARS-CoV-2 TestBaebies, Inc. · 510(k) 2026
- Simplexa COVID-19/ Flu A/B & RSV Direct (MOL4450)Diasorin Molecular, LLC · 510(k) 2025
- cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 SystemsRoche Molecular Systems, Inc. · 510(k) 2025
- cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid testRoche Molecular Systems, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.